Bristol Myers Squibb's Iza-bren Shows Promise in Lung Cancer Phase I Trials

Breakthrough in Lung Cancer Treatment: Iza-bren Shows Promise in Phase I Trials

Bristol Myers Squibb collaborates with SystImmune Inc. to advance the development of iza-bren (BL-B01D1), a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, in the treatment of non-small cell lung cancer (NSCLC). Recent findings from the global phase I US-Lung-101 study, presented at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, reveal promising preliminary safety and efficacy data. This study, which includes 107 patients primarily with heavily pre-treated advanced solid tumors, particularly metastatic or unresectable NSCLC, highlights the potential of iza-bren in a challenging patient population.

The results indicate that iza-bren achieves a confirmed response rate of 55% at a dosage of 2.5 mg/kg administered every three weeks, with a median progression-free survival of 5.4 months. Notably, the treatment demonstrates efficacy across different patient subgroups, with responses observed in both EGFR-mutated and EGFR wildtype patients. These findings are particularly significant as they come in the context of a heavily pre-treated cohort, underscoring the drug's potential to offer a new therapeutic option for patients who have exhausted other treatments. SystImmune's Chief Medical Officer, Jonathan Cheng, emphasizes the consistency of these results across a diverse global population, reinforcing the drug’s promise in the competitive oncology landscape.

In addition to the encouraging data for NSCLC, iza-bren has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA), further enhancing its development prospects. This designation is based on positive outcomes from earlier studies conducted in China and paves the way for expedited regulatory review. SystImmune is actively pursuing ongoing global registrational studies for additional indications, including first-line metastatic triple-negative breast cancer (TNBC) and second-line metastatic urothelial cancer. This multi-indication strategy aligns with Bristol Myers Squibb's commitment to addressing unmet medical needs in oncology, positioning both companies at the forefront of innovative cancer therapies.

As SystImmune continues its exploration of iza-bren, the collaboration with Bristol Myers Squibb exemplifies the importance of partnerships in biotechnology, particularly in the fight against cancer. Following these developments, stakeholders in the oncology field remain optimistic about the future of targeted therapies and the potential impact on patient outcomes. The safety profile of iza-bren, marked by manageable hematologic adverse events and no reports of interstitial lung disease, further solidifies its role as a promising candidate in the evolving landscape of cancer treatment.